Oculis (NASDAQ:OCS) Earns “Buy” Rating from Chardan Capital

Chardan Capital reiterated their buy rating on shares of Oculis (NASDAQ:OCS) in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a $28.00 target price on the stock.

Separately, HC Wainwright decreased their target price on shares of Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a research note on Thursday.

Oculis Stock Performance

Shares of NASDAQ:OCS opened at $18.77 on Thursday. The company has a market cap of $760.26 million, a price-to-earnings ratio of -9.73 and a beta of 0.02. The company has a 50-day moving average price of $20.92 and a 200-day moving average price of $16.97. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. Oculis has a 12 month low of $10.55 and a 12 month high of $23.08.

Oculis (NASDAQ:OCS) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.28). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. As a group, equities analysts anticipate that Oculis will post -2.09 EPS for the current year.

Institutional Investors Weigh In On Oculis

A number of institutional investors have recently made changes to their positions in the company. Bellevue Group AG purchased a new stake in Oculis in the fourth quarter worth approximately $170,000. XTX Topco Ltd purchased a new stake in Oculis in the fourth quarter worth approximately $225,000. Geode Capital Management LLC boosted its holdings in Oculis by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock worth $284,000 after purchasing an additional 1,800 shares during the last quarter. Citadel Advisors LLC bought a new position in Oculis in the fourth quarter worth approximately $389,000. Finally, Bank of America Corp DE raised its position in Oculis by 58.2% in the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock worth $493,000 after acquiring an additional 10,667 shares during the period. Hedge funds and other institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.